Impact of transcranial magnetic stimulation on motor function in children with acquired brain injury: a scoping review protocol

Chandrasekar Rathinam, Vikram Mohan, Peter Bill, Derick Yates, Rajat Gupta, and Janet Peirson

ABSTRACT

BACKGROUND

Children with severe acquired brain injury (ABI) require early and effective neurorehabilitation provision to promote a good long-term functional outcome. Transcranial magnetic stimulation (TMS) has been used to improve motor skills for children with cerebral palsy but there is limited material supporting its use in children with ABI who have a motor disorder.

OBJECTIVE

To systematically answer what the TMS intervention effects are on motor function in children with ABI as reported in the literature.

METHODS AND ANALYSIS

This scoping review will follow Arksey and O’Malley’s scoping review methodological framework. A comprehensive computerised bibliographic databases search will be performed in MEDLINE, EMBASE, CINAHL, Allied and Complementary Medicine, BNI, Ovid Emcare, PsycINFO, Physiotherapy Evidence Database, Cochrane Central Register using keywords related to TMS and children with ABI. Studies that examine the effect of TMS intervention on motor function as either a primary or secondary objective will be included for this review. Study design and publication detail, participant demographic details, type and severity of ABI and other clinical information, TMS procedure, associated therapy intervention, comparator/control parameters and the outcome measure used data will be gathered.

The International Classification of Functioning, Disability and Health for Children and Youth framework will be used to report the TMS effect in children with ABI. A narrative synthesis of the findings describing the therapeutic effects of TMS intervention, limitations and adverse effects will be synthesised and reported. This review will help to summarise the existing knowledge base and to guide further research areas. This review outcome may help to evolve therapists’ role to next-generation technology-based neurorehabilitation programmes.

ETHICS AND DISSEMINATION

No ethical approval is required for this review as we will be collecting data from previously published studies. We will present the findings at scientific conferences and publish in a peer-review journal.

BACKGROUND

Acquired brain injury (ABI) is the term used to describe traumatic and non-traumatic brain injuries that occur after birth and a period of typical development. In the UK, ABI accounts for 35,000 childhood presentations to emergency departments annually. Of these, 5% have moderate to severe brain injury. Children with severe ABI will often have movement difficulties caused by weakness, abnormal muscle tone, poor motor control, poor concentration, fatigue and other comorbidities. They may also have difficulties with speech, swallowing and cognitive impairment. A subgroup of children with ABI present with a stroke like presentation limiting their activity, balance, gait and fine motor skills. They are likely to develop tightness and contractures in both the upper and lower limbs. This impairment leads to functional difficulties including self-care, playing with and manipulating toys, socialising with and academic activities. During the acute phase, children with moderate to severe ABI frequently require a period of demanding medical and rehabilitative care to optimise their long-term capabilities and quality of life.
through neuroplasticity. This acute care can last up to 12 months following the initial brain injury which often requires a wide range of neurorehabilitation measures from a multidisciplinary team.

Early and effective neurorehabilitation provision promotes a good long-term functional outcome for children with ABI. Active rehabilitation begins as soon as they are medically stable. The typical rehabilitation includes facilitation of movements, postural control, postural care management, constraint-induced movement therapy (CIMT), strength training, dysphagia and communication management; and tone medications to improve motor and functional skills through neuroplasticity. Recent advances in technology enable clinicians to use functional electrical stimulation, virtual reality (VR) and transcranial magnetic stimulation (TMS) to improve motor skills for children with central nervous system-related movement disorders.

TMS is a non-invasive treatment technique. It is safe to use for children and adolescents with neurological conditions. It delivers repetitive magnetic pulses directly to specifically targeted brain areas through electromagnetic induction. TMS is applied over the scalp either on the same or opposite side to modulate cortical excitability through electromagnetic induction. In TMS, an electric charge is applied to a small coil and this produces a magnetic field perpendicular to the coil. This magnetic field creates an electrical current in the brain tissue parallel to the coil. This activates the localised neurons through cortical excitation. Low frequency TMS reduces cortical excitability but the high frequency increases it, thereby producing the desired therapeutic effect. Navigated repetitive TMS is delivered to a targeted brain area to change polarisation and it has been shown to influence cortical excitability many minutes after initial stimulation. This will help to facilitate, inhibit or interrupt the cortical network depending on the frequency and intensity of the stimulus, thus promoting a cortical function change through neuroplasticity.

TMS has been widely used in adult stroke rehabilitation to facilitate cortical excitability and to promote neuroplasticity. Early application of TMS (from 2 weeks to 2 months, 5–15 sessions; 1–10 Hz) coupled with other rehabilitation therapy intervention has been shown to result in decreased motor impairment, improved activity and participation level in the stroke population. TMS has been used to treat children with neuropsychiatric disorders including children on the autistic spectrum, those with attention deficit hyperactivity disorder, obsessive–compulsive disorder and also tics. A systematic review investigated the effectiveness of non-invasive brain stimulation for rehabilitation of children with cerebral palsy (CP). This review identified 4 studies that used repetitive TMS (5–10 sessions, with each session lasting between 10 and 20 min). Three studies used inhibitory low frequency repetitive TMS over the contralateral motor cortex and one study used both high and low frequency repetitive TMS over the primary motor area. A meta-analysis of the outcome measure indicated improved upper limb function following repetitive TMS.

It is worth noting that some literature includes children with CP as ABI. An injury to the brain occurs in very early life in CP, whereas in ABI the injury is sustained after a period of normal development. It could be argued that the description and presentation of CP is markedly different from those who sustained moderate to severe ABI at a later time in their childhood. Enhanced neuroplasticity in the developing brain may prove to be advantageous in rehabilitation following ABI. Structural and functional neural plasticity is attributed to change in regional volumes in brain cells or formation of neural pathways through synaptogenesis, axonal or dendritic sprouting and the creation of new neurons. Synaptic and intrinsic mechanism regulates neural excitability which influences neural plasticity. Metaplasticity, an activity-dependent modulation of synaptic plasticity was induced by TMS in adult neurological disorders such as stroke and Parkinson’s disease. TMS can be an effective tool to treat brain disorders through inducing metaplasticity. TMS coupled with regular rehabilitation could provide improved outcomes through neural plasticity and metaplasticity. If this is the case, TMS combined with intensive rehabilitation appears to be a promising new intervention approach with wider future applications for children with ABI. There is, however, limited material supporting its use in children with ABI who have a motor disorder.

The intervention effect in rehabilitation research has been widely reported using the International Classification of Functioning, Disability and Health for Children and Youth (ICF-CY) framework. The ICF-CY domain consists of body structures and function, activity, participation and contextual factors (environment and personal) which can be used to classify the level of functioning in childhood. This model can be applied to report the functional outcome of children and young people (CYP) with ABI who have impaired physical, cognitive and emotional difficulties and the impact on activity limitation and participation restriction following an intervention.

The overall objective of this scoping review will be to examine the literature relating to the therapeutic effect of TMS in children with ABI. The outcome of this review will be categorised according to the ICF-CY dimensions. This review will help to summarise the existing knowledge base and to identify areas requiring further research.

METHODS
This review protocol will follow both the Preferred Reporting Items for Systematic Reviews and Meta- Analyses extension for Scoping Reviews (PRISMA-ScR) checklist and Arksey and O’Malley’s scoping review approach. In addition, the PRISMA protocol guidelines will be followed to ensure scientific rigour (see online supplemental file).
Identifying the research question
The primary aim of this scoping review will be to characterise TMS intervention. We will specifically answer the question ‘what are the effects of TMS interventions on motor function in children with ABI as reported in the literature?’.

Identifying relevant studies

Search strategy
A copy of the full search strategy as run in Ovid Medline is provided in online supplemental appendix 1. This search will be modified as necessary to be completed in the following databases.

- Electronic database search: A comprehensive computerised bibliographic databases search will be performed in the following databases:
  - MEDLINE (1946–current).
  - EMBASE (1974 to current).
  - Cumulative Index to Nursing and Allied Health Literature.
  - Allied and Complementary Medicine (1985 to present).
  - Ovid Emcare (1994 to current).
  - PsycINFO (1806–current).
  - Physiotherapy Evidence Database.
  - Cochrane Central Register.
- Contacting the corresponding authors of the included articles and asking them to provide the details of any other TMS-related research studies in ABI either by their team or by their associates and research group.
- Citation Searching from the included individual studies.
- Other sources
  - The references included in the list of papers selected from the electronic database.
  - A handsearch will be carried out in specific key journals that have published the maximum number of relevant articles selected for this review. This option will only be carried out if there are more than three articles selected from a particular journal.
- Searching Dissertation Abstracts (using ProQuest), conference proceedings and abstracts related to TMS and contacting the researchers to provide any additional information.
- The following TMS equipment manufacturers/distributors will be contacted via email and asked for the details of any trials related to TMS in paediatric ABI population (Axilum Robotics, Brainbox, Brainsway, DEYMED Diagnosti¢ EB Neuro, eNeura, Jiangsu Aegean Technology, MAG & more, Magstim, MagVenture, Neurionics, Neurosoft, Nexstim, NIBBOT International, Remed, Sebers Medical, Shenzhen Yingchi Technology, Soterix Medical, Syneika, Xuzhou Kejian).

Eligibility criteria
The searches will be confined to children under 18 years old with ABI only. Some studies include the adolescent population (15–25 years) and the review team will contact the authors to seek data for the children under 18 years old only. If no response is received, the article will be excluded and this will be documented. All the subgroups of ABI including traumatic, non-traumatic and brain tumour will be included but children with CP will be excluded. If a study has children with CP along with the ABI population, the review team will exclude data related to the CP population. If such information is not clearly available, the review team will contact the authors to seek clarification. If no response is received, the article will be excluded and this will be documented.

Studies that examine the effect of TMS intervention on motor function as either a primary or secondary objective will be included. Research studies that include TMS for diagnostic purposes will be excluded.

All type of studies such as reviews, clinical trials, cohort studies, case series, case reports and technical reports will be included. No exclusion criteria will be set for language or publication years, and these studies will be considered if the title and abstracts have been written in English. The review team will contact the corresponding authors and request the information in English within 2 weeks. If no response is received, those studies will be excluded and this will be documented.

Study screening and selection
An electronic database search will be completed by the professional librarian and uploaded in the Ryaan software after removing duplicated studies. The collected titles and structured abstracts from the electronic database will be scrutinised independently by two reviewers by following the set inclusion and exclusion criteria. The excluded studies will be classified as irrelevant and the reasons will be documented. Grey literature and the trial database will be searched by two reviewers independently.

Full articles that meet the selection criteria from the above source will be collected from the NHS library services and the University of Birmingham library services. Two reviewers will decide which articles will be suitable for the final review and any disagreement will be managed after discussing with the third reviewer.

The selection process will be piloting 20% of the collected electronic and grey literature at the beginning to ensure reliable interpretation and agreement between the reviewers. Disagreement will be resolved with a consensus meeting. If no consensus reached, a third reviewer will be consulted. A PRISMA flow chart will be used to inform the selection process.

Charting the data/data extraction
After the screening, two reviewers will independently extract the data (CR and VM) in an Excel spreadsheet.
data extraction tool. Data extraction protocol will be piloted on the first five articles. This will help to maintain consistency in data extraction and to make the required changes in the data extraction tool. The above process will be documented. One of the reviewers will extract the data (CR) in an excel spreadsheet from the remaining included studies and the second reviewer (VM) will independently check the collected data.

The review team will gather data about
- Study design and publication detail (reviews, RCT, comparative study, case reports, technical reports, authors detail, year of publication, study location).
- Participants demographical, type of ABI and other clinical information.
- TMS procedure (technique, equipment specification, stimulation parameters such as coil placement, intensity, duration, frequency, adverse effects).
- Any associated therapy intervention (physiotherapy, occupational therapy, VR and other therapy techniques such as CIMT, bimanual therapy, gait training, etc) with or without TMS intervention.
- Comparator/control parameters.
- Outcome measures used in the individual studies and the relevant observation relating to ICF-CY domains.

This review will be aimed at identifying the changes in motor function of children with ABI. All of the motor function-related outcomes reported in the selected articles will be classified under ICF-CY domains. Additional details explaining how these outcomes were measured and at what time points these were collected will be reported. This review will not assess the risk of bias on the included studies but will report their level of evidence.

**Collating, summarising and reporting the results**

This review is expected to find heterogeneity across the studies, therefore, a narrative synthesis of the findings describing the therapeutic effects of TMS intervention, limitations, adverse effects and the gaps will be synthesised and reported. A table summarising ICF-CY domain for each study will be presented along with the narrative results.

**Patient and public involvement**

The review team consulted two parents of children with ABI in the design of this protocol. The review team will contact the Child Brain Injury Trust (CBIT), a national charity organisation for children with ABI (UK), when conducting the review and seek their help interpreting the findings and dissemination. Any recommendations made by the CBIT will be implemented.

**DISCUSSION**

Our protocol explains the methodology to guide our review. The outcome of the review is carefully planned and documented to ensure transparency and research integrity to allow replication.26

From this scoping review, the review team will provide a descriptive analysis of TMS for children with ABI and how this has been delivered. This review will help to understand the range of TMS dose which includes frequency, intensity, duration, stimulation site, motor function outcome and the corresponding actual or proposed mechanism. Due to the known variation in neuroplastic ability in the developing brain, it will be important to understand the TMS influence on functional motor recovery across different age groups within our overall age range.

This scoping review will also provide some insight related to the factors influencing TMS outcome. Age, gender, duration of illness, concordance with the treatment plan, associated comorbidities such as increased tone, tightness/contracture in joints and concurrence with the treatment may be some of the patient-related factors that influence the TMS outcome. Anatomical variations such as skull size, previous neurosurgeries and structural changes in brain will be a challenge to apply TMS. These procedure-related factors associated with the illness-related factors such as children with a high level of motor disability, medications to manage tone, seizure activity and other conditions may have an impact of the therapeutic outcome. Stimulation factors such as site of stimulation, intensity, frequency, duration and the number of stimulation episode will be other factors determining the outcome strength. The above factors will be observed and reported in our review.

This information will guide future trial development with TMS treatment components that are being commonly used and how they are being delivered. Such treatment information can be organised in the Template for Intervention Description and Replication checklist to assist future research work to plan and report TMS intervention. This review will help to conduct high-quality patient and public involvement for future studies, designing feasibility studies, and may guide to identify eligible CYP with ABI for TMS intervention.

Our scoping review has certain limitations. The majority of the studies on ABI included children with CP and the review team is not intending to include this population. Any related studies will be excluded and the associated knowledge will be missed. It may be possible that there are a very limited number of studies related to TMS in ABI and this may lead to inconclusiveness about the predicted motor response. This could be because of small sample size, duration and techniques of TMS, and also the associated comorbidities such as mental health issues, fatigue, cognitive and memory problems. Observed limitations will be reported and mitigated in our future systematic review.

This review outcome may help to develop therapists’ role from conventional hands-on therapy provision to next-generation technology-based neurorehabilitation programmes. It is also likely to have an impact on CYP access to advanced technology during their acute phase
to aid enhanced recovery and help improve their patient experience.

**Twitter** Chandrasekar Rathinam @ChandrasekarBCH, Vikram Mohan @VikramMohan10 and Derick Yates @DJY_LIB_EBP

**Contributors** CR, VM and JP: involved in study conceptualisation. CR, VM, JP, PB and RG: responsible for study design and protocol development. CR and VM: responsible for screening, selecting articles and data entry. CR, VM, JP, PB and RG: responsible for data interpreting and reporting. DY: responsible for constructing search strategy and conducting searches. CR, VM, PB, RG and JP: responsible for preparing final manuscript. CR: guarantor of the review. All authors will read, provide feedback and approve the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data sharing not applicable as no datasets generated and/or analysed for this study.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article published under the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID IDs**

Chandrasekar Rathinam http://orcid.org/0000-0002-0049-8430

Vikram Mohan http://orcid.org/0000-0002-9067-2817

Derick Yates http://orcid.org/0000-0002-5715-7020

Rajat Gupta http://orcid.org/0000-0001-5111-7821

**REFERENCES**


Appendix: Search Strategy: Ovid MEDLINE(R) ALL <1946 to Present>

1  exp Child/
2  exp Adolescent/
3  (p?ediatric* or child* or youth* or adolescen* or juvenile* or teenage* or boy* or girl*).ab,ijn,ti.
4  1 or 2 or 3
5  exp Brain Injuries/ or exp Craniocerebral Trauma/ or exp Skull Fractures/
6  ((brain or head or skull or cranio* or cranial or occipital) adj3 (injur* or trauma* or fracture*)).ab,ti.
7  exp Meningitis/
8  Meningitis.ab,ti.
9  exp Encephalitis/
10 Encephalitis.ab,ti.
11 exp Stroke/
12 (Stroke or cerebrovascular accident*).ab,ti.
13 exp Arteriovenous Malformations/
14 Arteriovenous Malformation*.ab,ti.
15 exp Intracranial Aneurysm/
16 ((intracranial or brain or cerebral) adj3 Aneurysm*).ab,ti.
17 exp Cerebral Hemorrhage/ or exp Intracranial Hemorrhages/
18 ((intracranial or brain or cerebral) adj3 H?emorrhage*).ab,ti.
19 exp Hypoxia, Brain/ 14043
20 ((brain or cerebral or encephalopath*) adj3 (hypox* or anox*)).ab,ti.
21 exp Asphyxia/
"asphyxia**".ab,ti.

exp Brain Neoplasms/ or exp Central Nervous System Neoplasms/

(((brain or cerebral or CNS or central nervous system) and (tumor* or glioma* or blastoma* or sarcoma* or cancer* or neoplasm* or astrocytoma* or ependymoma* or glioblastoma* or oligoastrocytoma* or oligodendroglioma* or Meningioma* or medulloblastoma*)) or "posterior fossa syndrome").ab,ti.

5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24

exp Transcranial Magnetic Stimulation/

(Transcranial adj2 magnetic adj2 stimulation*).ab,ti.

exp Transcranial Direct Current Stimulation/

(noninvasive adj2 brain adj2 stimulation).ab,ti.

(noninvasive adj2 cerebral adj2 stimulation).ab,ti.

(Transcranial adj2 direct adj2 Current adj2 Stimulation).ab,ti.

(electromagnetic induction and brain).ab,ti.

(TMS or rTMS or NIBS or NrTMS).ab,ti.

(transcranial adj2 electric* adj2 stimulation).ab,ti.

((Anodal or Cathodal) and stimulation TDCS).ab,ti.

transcranial random noise stimulation.ab,ti.

transcranial alternating current stimulation.ab,ti.

Theta Burst Stimulation.ab,ti.

26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 32106

4 and 25 and 39

******************************************
Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

<table>
<thead>
<tr>
<th>SECTION</th>
<th>ITEM</th>
<th>PRISMA-ScR CHECKLIST ITEM</th>
<th>REPORTED ON PAGE #</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE</td>
<td>Title 1</td>
<td>Identify the report as a scoping review.</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>Structured summary 2</td>
<td>Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.</td>
<td>1</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>Rationale 3</td>
<td>Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.</td>
<td>1 - 2</td>
</tr>
<tr>
<td></td>
<td>Objectives 4</td>
<td>Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.</td>
<td>2</td>
</tr>
<tr>
<td>METHODS</td>
<td>Protocol and registration 5</td>
<td>Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Eligibility criteria 6</td>
<td>Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Information sources* 7</td>
<td>Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Search 8</td>
<td>Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.</td>
<td>Appendix</td>
</tr>
<tr>
<td></td>
<td>Selection of sources of evidence† 9</td>
<td>State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Data charting process‡ 10</td>
<td>Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.</td>
<td>3 - 4</td>
</tr>
<tr>
<td></td>
<td>Data items 11</td>
<td>List and define all variables for which data were sought and any assumptions and simplifications made.</td>
<td>4</td>
</tr>
<tr>
<td>SECTION</td>
<td>ITEM</td>
<td>PRISMA-ScR CHECKLIST ITEM</td>
<td>REPORTED ON PAGE #</td>
</tr>
<tr>
<td>---------</td>
<td>------</td>
<td>---------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Critical appraisal of individual sources of evidence§</td>
<td>12</td>
<td>If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).</td>
<td>N/A</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>13</td>
<td>Describe the methods of handling and summarizing the data that were charted.</td>
<td>4</td>
</tr>
<tr>
<td>RESULTS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection of sources of evidence</td>
<td>14</td>
<td>Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.</td>
<td>3</td>
</tr>
<tr>
<td>Characteristics of sources of evidence</td>
<td>15</td>
<td>For each source of evidence, present characteristics for which data were charted and provide the citations.</td>
<td>N/A</td>
</tr>
<tr>
<td>Critical appraisal within sources of evidence</td>
<td>16</td>
<td>If done, present data on critical appraisal of included sources of evidence (see item 12).</td>
<td>N/A</td>
</tr>
<tr>
<td>Results of individual sources of evidence</td>
<td>17</td>
<td>For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.</td>
<td>N/A</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>18</td>
<td>Summarize and/or present the charting results as they relate to the review questions and objectives.</td>
<td>3 - 4</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary of evidence</td>
<td>19</td>
<td>Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.</td>
<td>4 - 5</td>
</tr>
<tr>
<td>Limitations</td>
<td>20</td>
<td>Discuss the limitations of the scoping review process.</td>
<td>4</td>
</tr>
<tr>
<td>Conclusions</td>
<td>21</td>
<td>Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.</td>
<td>4 - 5</td>
</tr>
<tr>
<td>FUNDING</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>22</td>
<td>Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.</td>
<td>5</td>
</tr>
</tbody>
</table>

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.
* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.
† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with information sources (see first footnote).
‡ The frameworks by Arksey and O’Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.
§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of “risk of bias” (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence.
that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy

document).